Medoclav (Amoxicillin, Clavulanic Acid)

Amoxicillin interferes with bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, which stops peptidoglycan cross‑linking. Clavulanic acid is a β‑lactamase inhibitor that binds irreversibly to enzymes that would otherwise destroy amoxicillin, thereby extending the antibiotic’s activity against β‑lactamase‑producing organisms.

The dose of Medoclav is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal and hepatic function, and local antimicrobial guidelines. No fixed regimen is provided here; the prescriber tailors the dosage to each individual case.

Medoclav is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if clearly needed. Limited data are available for breastfeeding, so the benefit‑risk balance should be evaluated by the healthcare professional.

To order Medoclav, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including cold‑chain logistics if required) and assists with import documentation.

Compared with plain amoxicillin, Medoclav adds clavulanic acid, which protects the antibiotic from β‑lactamase enzymes produced by resistant bacteria. This expands the spectrum to include many β‑lactamase‑producing strains, making it more effective for mixed‑organism infections than amoxicillin alone, while retaining a safety profile similar to other penicillins.

Medoclav must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If the product is to be used after a prolonged storage period, inspect it for any discoloration or particulate matter before administration.

Medoclav is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional under aseptic conditions, typically diluted in an appropriate compatible IV fluid and infused over the time period recommended in the prescribing information. Administration details are determined by the treating physician.

The most serious adverse reactions include anaphylaxis or other severe allergic responses, severe hepatic injury, and Clostridioides difficile‑associated colitis, which can cause life‑threatening diarrhea. Patients should be monitored for signs of rash, difficulty breathing, jaundice, or persistent watery stools, and any such symptoms should prompt immediate medical evaluation.

Medoclav should be avoided in individuals with a known hypersensitivity to any penicillin, β‑lactamase inhibitor, or any component of the formulation. Patients with a history of severe allergic reactions to β‑lactam antibiotics should not receive this product. Caution is also advised for patients with severe renal or hepatic impairment, where alternative therapy may be preferred.